Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Therapeutic Potential of Adipose-derived Stem Cells in the Treatment of Pulmonary Diseases.

Abdul Halim NSS., Yahaya BH., Lian J.

Laboratory Study on Chronic Inflammation, Immune Modulation, published in Curr Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Curr Stem Cell Res Ther (2022)
Country
United Arab Emirates
Reported sample size
—
Source database
PubMed
PMID
34387168
DOI
10.2174/1574888X16666210812145202
Citations
2

Abstract (original English)

Stem cells derived from adipose tissues (ADSCs) have emerged as an ideal candidate for various models of respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease (COPD), and acute respiratory distress syndrome. ADSCs have qualities that may make them better suited for treating inflammatory lung diseases than other MSCs. ADSCs show a lower senescence ratio, higher proliferative capacity and stability in terms of their genetic and morphology during long-term culture over Bone Marrow-derived Mesenchymal Stem Cells (BMMSCs). With enhanced research methodologies, the beneficial benefits of ADSCs appear to be restricted to their capacity to engraft, differentiate, and be connected to trophic factor secretion. These trophic factors influence treatment and regenerative results in a variety of lung inflammatory disorders. Taken together, these particular qualities of ADSCs make them significantly relevant for clinical applications. This article discusses a recent advance of ADSCs biology and their translational application, emphasizing their anti-inflammatory, immunomodulatory and regenerative properties, particularly on lung inflammatory diseases. Besides, the relevant advancements made in the field, the regulatory aspects, and other challenges and obstacles will be highlighted.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesAdipose TissueHumansLung DiseasesMesenchymal Stem CellsStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research